Travere Therapeutics, Inc.
TVTXUS売上高
$491M
百万USD
営業利益
$-63M
百万USD
純利益
$-26M
百万USD
ROE
-22.2%
最新FY
EPS
$-0.29
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | $47M | $-54M | $-0.96 |
| FY2021 | Q2 | $55M | $-39M | $-0.64 |
| FY2021 | Q3 | $68M | $-36M | $-0.59 |
| FY2021 | FY | $227M | $-180M | $-3.01 |
| FY2022 | Q1 | $48M | $-76M | $-1.20 |
| FY2022 | Q2 | $54M | $-67M | $-1.05 |
| FY2022 | Q3 | $53M | $-70M | $-1.09 |
| FY2022 | FY | $212M | $-278M | $-4.37 |
| FY2023 | Q1 | $57M | $-86M | $-1.27 |
| FY2023 | Q2 | $60M | $-86M | $-1.13 |
| FY2023 | Q3 | $37M | $151M | $1.97 |
| FY2023 | FY | $145M | $-111M | $-1.50 |
| FY2024 | Q1 | $41M | $-136M | $-1.76 |
| FY2024 | Q2 | $54M | $-70M | $-0.91 |
| FY2024 | Q3 | $63M | $-55M | $-0.70 |
| FY2024 | FY | $233M | $-322M | $-4.08 |
| FY2025 | Q1 | $82M | $-41M | $-0.47 |
| FY2025 | Q2 | $114M | $-13M | $-0.14 |
| FY2025 | Q3 | $165M | $26M | $0.28 |
| FY2025 | FY | $491M | $-26M | $-0.29 |
| FY2026 | Q1 | $127M | $-37M | $-0.40 |
財務データ
| 指標 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 売上高 | - | - | $164M | $175M | $198M | $227M | $212M | $145M | $233M | $491M |
| 営業利益 | $-58M | $-54M | $-80M | $-137M | $-176M | $-162M | $-267M | $-388M | $-324M | $-63M |
| 純利益 | $-48M | $-60M | $-103M | $-146M | $-169M | $-180M | $-278M | $-111M | $-322M | $-26M |
| 総資産 | $525M | $520M | $709M | $605M | $607M | $777M | $673M | $789M | $594M | $605M |
| 純資産 | - | - | - | - | - | - | - | - | - | - |
| 自己資本 | $308M | $293M | $318M | $221M | $211M | $302M | $43M | $201M | $59M | $115M |
| 営業CF | - | $7M | $-25M | $-58M | $-43M | $-15M | $-186M | $-280M | $-237M | $38M |
| EPS | $-1.29 | $-1.54 | $-2.54 | - | - | $-3.01 | $-4.37 | $-1.50 | $-4.08 | $-0.29 |
| BPS | $8.08 | $7.39 | $7.68 | $5.13 | $3.51 | $4.78 | $0.66 | $2.64 | $0.67 | $1.24 |
| ROE | -15.6% | -20.4% | -32.3% | -66.2% | -80.2% | -59.6% | -649.9% | -55.5% | -544.3% | -22.2% |